Myrbetriq® (mirabegron) – Expanded indication
April 27, 2018 - The FDA approved Astellas’ Myrbetriq (mirabegron), for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in combination with the muscarinic antagonist Vesicare® (solifenacin).
Top